antibody

Anti-NF-Kappa B (p105/p50) NFKB1 Rabbit Monoclonal Antibody

M00283

100 µl

monoclonal

domestic rabbit

nonconjugated

ID-14

human, mouse, rat

western blot, immunohistochemistry

Anti-NF-Kappa B (p105/p50) NFKB1 Rabbit Monoclonal Antibody

100 µl

Monoclonal

ID-14

Rabbit

Human, Mouse, Rat

IHC, WB

WB 1:500-1:2000 .IHC 1:50-1:200

Boster Bio Anti-NF-Kappa B (p105/p50) NFKB1 Rabbit Monoclonal Antibody catalog # M00283. Tested in IHC, WB applications. This antibody reacts with Human, Mouse, Rat.

Actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.

NFKB1

P19838

A synthesized peptide derived from human NF-κB (p105/p50)

Liquid

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.

Affinity-chromatography

Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Nuclear factor NF-kappa-B p105 subunit

Nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; Nuclear factor NF-kappa-B p50 subunit; NFKB1;

105356 MW

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.

Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).

Apoptosis, Apoptotic Markers, Cancer, Cell Biology, Cell Death, Epigenetics and Nuclear Signaling, Immunology, Innate Immunity, Intracellular, Macrophage / Inflamm., Nfkb Pathway, Nuclear Signaling, Nuclear Signaling Pathways, Signal Transduction, Signaling Pathway, Transcription, Transcription Factors